| Date | Title | Description |
| 13.02.2026 | China’s Bio-Thera Gets EU’s Marketing Approval for Its Inflammatory Autoimmune Disease Drug | (Yicai) Feb. 13 -- Chinese biopharmaceutical company Bio-Thera Solutions’ Gotenfia has received regulatory approval from the European Union for the treatment of several chronic inflammatory autoimmune diseases.
Bio-Thera received the market... |
| 05.02.2026 | January 2026's top 10 European tech deals you need to know about | European tech startups raised €5 billion across 265 deals in January 2026, marking a 9 per cent drop in deal volume and a 24 per cent decline in funding compared with the same month year before.
Regionally, Germany stood out, with startups ... |
| 07.01.2026 | Alvotech Secures $100 Million for Biosimilar Expansion, Fuels Global R&D | Alvotech secured a $100 million term loan. GoldenTree Asset Management led the financing. This boosts liquidity. It supports critical R&D investments. The funds also back global product launches through 2026. Alvotech develops biosimila... |
| 06.01.2026 | Alvotech Secures $100 Million Term Loan Facility Led By GoldenTree | Alvotech announced it has entered into a $100 million senior term loan facility maturing in December 2027, a financing it expects will strengthen liquidity and support execution of its strategic priorities, including advancing its R&D p... |
| 02.01.2026 | Icelandic BioTech Alvotech secures €100 million term loan facility to bolster liquidity and R&D investment | Alvotech, a Reykjavík-based BioTech company specialising in the development and manufacture of biosimilar medicines, has secured a €100 million senior term loan facility to strengthen liquidity and support the execution of its strategic pri... |
| 17.10.2025 | New leadership drives growth in biotech and AI startups |
Mark Pruzanski, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of Alentis, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-... |
| 05.06.2025 | Alvotech, Dr Reddy’s ink pact to co-develop Biosimilar for cancer treatment | - |
| 20.03.2025 | Alvotech Acquires Xbrane’s R&D Operations in Sweden | Alvotech (NASDAQ: ALVO), a Reykjavik, Iceland-based biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, acquired Xbrane’s R&D operations and the biosimilar candidate XB003.
The... |
| 15.08.2024 | Revolutionizing Pharma: PLAIO's €4.3 Million Leap into AI-Driven Supply Chains | In the heart of Reykjavik, a quiet revolution is brewing. PLAIO, an Icelandic startup, has secured €4.3 million in funding to reshape the pharmaceutical supply chain landscape. This investment, led by Iðunn, a venture capital fund, marks a ... |
| 14.08.2024 | Iceland's PLAIO raises €4.3M for AI-driven pharma supply chain solutions | Iceland-founded AI-assisted decision support platform for the pharmaceutical industry PLAIO has raised €4.3 million in an oversubscribed round.
The company was co-founded by industry veterans and academics with over 25 years of experience i... |
| 22.05.2024 | Alvotech and Dr. Reddy’s partner to commercialize AVT03 | Alvotech, a global player in biosimilar medicines, and Dr Reddy’s Laboratories SA, wholly-owned subsidiary of Dr Reddy’s Laboratories, have entered into a license and supply agreement for the commercialisation of AVT03, Alvotech’s biosimila... |
| 05.03.2024 | Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET | - |
| 26.02.2024 | Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share | - |
| 31.07.2023 | Alvotech Completes $100 Million Convertible Bond Private Placement | - |
| 09.02.2023 | EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) | Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA)
The EMA’s acceptance for filing marks a key milestone in making an additional treatment op... |
| 23.01.2023 | Alvotech Completes $137 Million Private Share Placement | /EIN News/ -- REYKJAVIK, Iceland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the comple... |
| 23.01.2023 | Alvotech Completes $137 Million Private Share Placement | - |
| 16.12.2022 | Alvotech Completes $59.7 Million Private Placement | - |
| 16.11.2022 | Alvotech Secures Financing Facilities of Approximately $136 Million | - |
| 10.05.2022 | Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse | The Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo
Róbert Wessman, Chair... |
| 07.12.2021 | Oaktree Acquisition II : Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company - Form 8-K | Alvotech and Oaktree Acquisition Corp. II Announce
Merger Agreement to Create a Leading Publicly-Traded
Global Biopharmaceutical Company
• Alvotech is a leading pure play biosimilar platform focused on the development and manufacture of hig... |
| 26.11.2021 | Róbert Wessman-led Aztiq and Innobic join forces in $475m acquisition of Lotus Pharmaceutical and Adalvo to create a global pharmaceutical powerhouse | REYKJAVÍK, Iceland, Nov. 26, 2021 /PRNewswire/ -- Aztiq ("Aztiq"), a healthcare investor led by Alvogen Founder and Chairman Róbert Wessman, and Innobic (Asia) Company Limited ("Innobic"), a life sciences subsidiary of T... |
| 26.11.2021 | Róbert Wessman-led Aztiq and Innobic join forces in $475m acquisition of Lotus Pharmaceutical and Adalvo to create a global pharmaceutical powerhouse | REYKJAVÍK, Iceland, Nov. 26, 2021 /PRNewswire/ -- Aztiq ("Aztiq"), a healthcare investor led by Alvogen Founder and Chairman Róbert Wessman, and Innobic (Asia) Company Limited ("Innobic"), a life sciences subsidiary of T... |
| 08.07.2021 | Alvotech Initiates Clinical Studies for AVT04, A Proposed Biosimilar to Stelara® (Ustekinumab) | Approximately 530 participants will be enrolled in a comparative, confirmatory efficacy and safety study for AVT04 in plaque psoriasis, across Central and Eastern European countries.
AVT04 Pharmacokinetic (PK) comparability study in approxi... |
| 28.06.2021 | Alvotech Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn | Funds provide additional resources and runway for advancing the company’s biosimilar pipeline
HONG KONG SAR – Media OutReach – 28 June 2021 – Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreeme... |
| 25.06.2021 | Alvotech : Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn | Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m covertible bond issued on December 14, 2018. Bondholders have exercised their conversion rights on approximat... |
| 18.05.2021 | AbbVie is facing the biggest challenge yet to its best-selling medicine, Humira, as an unlikely Icelandic drugmaker launches a legal fight over 'outrageous' patents and the CEO gets grilled by Congres... | AbbVie CEO Richard A. Gonzalez. AP Photo/Pablo Martinez Monsivais This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
AbbVie, the maker of the mega-blockbuster drug Humira, is faci... |
